The FDA approved AquaBounty Technologies’ New Animal Drug application for the production, sale and consumption of its salmon. Moreover, the agency looked into environmental impacts of approving the said application and found that its approval would not have a significant impact on the environment of the United States. This is primarily due to a number of containment measures set by AquaBounty to ensure that its salmon would not escape or establish themselves in the wild.
AquaBounty Chief Executive Officer Ronald L. Stotish, Ph.D. calls his company’s AquAdvantage Salmon a “game-changer” as the said salmon has been genetically enhanced for fish to reach market size in lesser time than a conventionally farmed Atlantic salmon. At the same time, the company is introducing an alternative approach to fish farming that does not involve the exploitation of the oceans.
The AquAdvantage salmon was said to have descended from a stock originating from the Bay of Fundy, giving it a mild delicate flake and firm meat. Currently, the U.S. imports more than 90 percent of all the seafood the country regularly consumes. Moreover, more than 95 percent of the Atlantic salmon consumed in the country is imported. With this new genetically engineered salmon, AquaBounty hopes to help the domestic aquaculture industry become more economically viable.